Evidence map›Paper›PMID 39592316›Full record

ArticleVaccine2025

Vaccine value profile for schistosomiasis.

Gavin Yamey, Kaci Kennedy McDade, Roy M Anderson, Sarah M Bartsch, Maria Elena Bottazzi, David Diemert, Peter J Hotez, Bruce Y Lee, Donald McManus, Adebayo J Molehin and 8 more

Abstract read
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Plant-Derived Terpenes as Emerging Therapeutics Against Schistosomiasis.International journal of molecular sciences · 2026
    Review
  4. Use of a cytochrome P450 humanized mouse model to refine schistosomiasis drug discovery.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Gavin YameyDuke Global Health Institute, Duke University, Durham, NC, United States. Electronic address: gavin.yamey@duke.edu.
Kaci Kennedy McDadeDuke Global Health Institute, Duke University, Durham, NC, United States. Electronic address: kaci.kennedy.mcdade@duke.edu.
Roy M AndersonFaculty of Medicine, School of Public Health, Imperial College London, London, United Kingdom. Electronic address: roy.anderson@imperial.ac.uk.
Sarah M BartschPublic Health Informatics, Computational, and Operations Research and Center for Advanced Technology and Communication in Health, City University of New York Graduate School of Public Health and Health Policy, New York City, NY, United States. Electronic address: sbartsch1029@gmail.com.
Maria Elena BottazziNational School of Tropical Medicine, Baylor College of Medicine, Texas Children's Hospital Center for Vaccine Development, Houston, TX, United States. Electronic address: bottazzi@bcm.edu.
David DiemertSchool of Medicine and Health Sciences, George Washington University, Washington, D.C., United States. Electronic address: ddiemert@gwu.edu.
Peter J HotezNational School of Tropical Medicine, Baylor College of Medicine, Texas Children's Hospital Center for Vaccine Development, Houston, TX, United States. Electronic address: hotez@bcm.edu.
Bruce Y LeePublic Health Informatics, Computational, and Operations Research and Center for Advanced Technology and Communication in Health, City University of New York Graduate School of Public Health and Health Policy, New York City, NY, United States. Electronic address: bruceleemdmba@gmail.com.
Donald McManusQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Electronic address: Don.McManus@qimrberghofer.edu.au.
Adebayo J MolehinDepartment of Microbiology & Immunology, Midwestern University, Glendale, AZ, United States. Electronic address: amoleh@midwestern.edu.
Meta RoestenbergLeiden University Medical Centre, Leiden, Netherlands. Electronic address: M.Roestenberg@lumc.nl.
David RollinsonGlobal Schistosomiasis Alliance, London, United Kingdom. Electronic address: d.rollinson@nhm.ac.uk.
Afzal A SiddiquiCenter for Tropical Medicine & Infectious Diseases, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX, United States. Electronic address: Afzal.Siddiqui@ttuhsc.edu.
Miriam TendlerLaboratory of Research and Development of Anti-Helminth Vaccines, Oswaldo Cruz Institute (Fiocruz), Rio de Janeiro, Brazil. Electronic address: tendlermiriam@gmail.com.
Joanne P WebsterDepartment of Pathobiology and Population Sciences, Royal Veterinary College, University of London, United Kingdom. Electronic address: jowebster@rvc.ac.uk.
Hong YouQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Electronic address: Hong.You@qimrberghofer.edu.au.
Raphaël M ZellwegerInternational Vaccine Institute, Seoul, Korea. Electronic address: raphael.zellweger@ivi.int.
Caroline MarshallWorld Health Organization, Geneva, Switzerland.

Funding

A Vaccine for Schistosomiasis, "SchistoShield"R44AI103983 · NIAID · PAI LIFE SCIENCES, INC. · PI CARTER, DARRICK ALBERT, SIDDIQUI, AFZAL A · 2016 to 2022
$5.5M
Experimental Molecular Vaccines for SchistosomiasisR01AI071223 · NIAID · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI SIDDIQUI, AFZAL A · 2008 to 2012
$2.6M
Process Development on a Schistosomiasis Vaccine, SchistoShield???R43AI103983 · NIAID · PAI LIFE SCIENCES, INC. · PI CARTER, DARRICK ALBERT, SIDDIQUI, AFZAL A · 2013 to 2014
$600k
Production and Validation of Sj-p80 as a Veterinary Schistosomiasis VaccineR43AI142908 · NIAID · PAI LIFE SCIENCES, INC. · PI GRAY, SEAN ALEX, SIDDIQUI, AFZAL A · 2019 to 2019
$225k
Schistosome Calpain as a Vaccine CandidatesR15AI050534 · NIAID · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI SIDDIQUI, AFZAL A · 2001 to 2002
$190k
Gates Foundation INV-005318NIAID NIH HHS R01 AI071223NIAID NIH HHS R15 AI050534NIAID NIH HHS R43 AI103983NIAID NIH HHS R43 AI142908NIAID NIH HHS R44 AI103983Wellcome TrustWorld Health Organization 001
6 · The paper itself

Abstract

Schistosomiasis is caused by parasitic flatworms (Schistosoma). The disease in humans can be caused by seven different species of Schistosoma: S. mansoni, S. japonicum, S. haematobium, S. malayensis, S. mekongi, S. guineensis and S. intercalatum, as well as by hybrids between species, including livestock schistosome species. People are infected when exposed to infested water and the parasite larvae penetrate the skin. Poor and rural communities are typically the most affected, and the general population who lives in affected areas and is exposed to contaminated water is at risk. Areas with poor access to safe water and adequate sanitation are also at heightened risk. About 236.6 million people required treatment for schistosomiasis in 2019-mostly people living in poor, rural communities, especially fishing and agricultural communities. This 'Vaccine Value Profile' (VVP) for schistosomiasis is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic, and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships, and multi-lateral organizations. All contributors have extensive expertise on various elements of the schistosomiasis VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.

Indexed as

SchistosomaSchistosomiasisVaccinesAnimalsHumansVaccinesNeglected tropical diseasesParasitic infectionSchistosomiasisVaccine value

Identifiers

PMID39592316
PMCPMC11754535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.